International Cancer Patient Coalition

Kenya



Prostate Cancer Factsheet: Insights & Key Developments

Key Insights on Prostate Cancer Care and Infrastructure

Core Pillars:

1. Infrastructure
2. Treatment Access, Research Funding and Awareness Campaigns
3. Survival Rates, Early Detection and Palliative Care
4. Utilization of Biomarkers
5. Clinical Guidelines
6. Reimbursement
7. Prostate Cancer Screening

Prostate cancer remains one of the most prevalent cancers worldwide, affecting millions of individuals each year. Despite advancements in diagnostics, treatment, and awareness, disparities in access to care, molecular testing, and specialized centers persist.

This factsheet provides a comprehensive overview of key pillars shaping Prostate cancer care, including specialized infrastructure, treatment accessibility, research funding, early detection, and palliative care.

- **Incidence share:** Among the top 5 cancers in Kenyan men.
- **Incidence rate:** Approximately 24 per 100,000 men per year.
- **Total new cases (2022):** Around 3,400 men.
- **Daily diagnoses (2022):** Approximately 9–10 men per day.
- **Deaths (2022):** Around 1,700 men.
- **5-year survival rate:** Estimated between 30–50%, due to late-stage diagnosis.
- **Most affected age group:** Primarily men aged 65 and above.
- **Screening participation:** Very limited PSA screening; no organized national program.

International Cancer Patient Coalition

Kenya

Infrastructure



Strengths

- Major urban areas like Nairobi, Kisumu, and Mombasa have established cancer centers such as Kenyatta National Hospital, Aga Khan University Hospital, and Nairobi Hospital.
- Ongoing investment in cancer units across counties (e.g., Meru, Machakos) indicates decentralization efforts.

Weakness

- Lack of radiotherapy units and urologists outside major cities causes delays in diagnosis and treatment.
- Diagnostic equipment (MRI, PET scans, biopsy kits) are limited and sometimes non-functional due to maintenance gaps.

S W O T

Opportunity

- Public-private partnerships can strengthen diagnostic infrastructure in tier-2 and tier-3 counties.
- Expansion of mobile health units and tele-oncology to bridge access gaps in rural areas.

Threats

- Brain drain of specialists to private sector or overseas limits workforce development.
- Political instability and funding diversion can derail ongoing infrastructure projects.

5. Advanced nationwide infrastructure, widespread availability in public and private sectors, integration with clinical practice.

4. Strong infrastructure in major hospitals and cancer centers, some regional disparities.

3. Moderate infrastructure, primarily in private settings or research institutions.

2. Limited infrastructure, available only in select centers or for high-cost private testing.

1. Minimal or no infrastructure, testing mostly unavailable or sent abroad.

Country	Specialized Centers	Genetic & Molecular Testing Infrastructure
South Africa	3	3
Kenya	1	2
Nigeria	1	2
Egypt	2	3
Morocco	2	2
Algeria	2	2
Ethiopia	1	1
India	3	4
Japan	4	4
South Korea	4	4
China	4	4
Thailand	3	3
Singapore	4	4
United Kingdom	4	4
Germany	5	4
France	4	4
Netherlands	5	4
Sweden	5	4
Italy	4	3
Spain	4	3
Poland	4	3
Mexico	2	3
Brazil	3	3
Argentina	3	3
Chile	3	3
Colombia	2	3
United States	5	5
Canada	5	4
Australia	4	4
New Zealand	4	4
Greece	4	3
Rwanda	1	1
Uganda	1	1
Serbia	3	3
Saudi Arabia	4	4
UAE	4	3
Syria	1	1
Indonesia	2	2
Vietnam	3	3
Philippines	2	2
Russia	3	3
Malaysia	3	3

International Cancer Patient Coalition

Kenya

Treatment Access, Research Funding and Awareness Campaigns



Strengths

- Cancer is recognized as a priority under Kenya's Universal Health Coverage agenda.
- NGOs, churches, and advocacy groups (like KENCO, Faraja Cancer Support) conduct prostate health outreach.

Weakness

- Chemotherapy, hormone therapy, and even surgery are often unaffordable or unavailable in public hospitals.
- Minimal prostate cancer-specific research funding compared to HIV/AIDS or maternal health.

S W O T

Opportunity

- Scale-up of national and county cancer awareness days targeting men over 50.
- Encourage collaboration between local universities and international cancer research networks.

Threats

- Misconceptions around prostate cancer (e.g., link to sexual performance) reduce participation in awareness drives.
- Resource competition with communicable diseases slows investment in NCDs like prostate cancer.

5. Strong healthcare infrastructure with comprehensive treatment access, high research funding, and nationwide awareness campaigns. Patients have access to advanced therapies, clinical trials, and widespread early detection programs.

4. Well-developed system with good treatment availability, strong research funding, and effective but regionally focused awareness campaigns. Some disparities may exist in rural areas or between public and private sectors.

3. Moderate development, with specialized treatments available in major hospitals, research funding concentrated on specific cancers, and occasional but limited awareness efforts. Healthcare access may be restricted by cost or geography.

2. Limited system where cancer treatment is available only in select urban centers, research funding is minimal or sporadic, and awareness campaigns are rare or underfunded. Patients often face long wait times or financial barriers.

1. Poor infrastructure with severe barriers to treatment, little to no research funding, and lack of structured awareness campaigns. Cancer care is largely inaccessible, with many patients relying on out-of-pocket expenses or external aid.

Country	Treatment Access	Research Funding	Awareness Campaigns
South Africa	3	3	3
Kenya	1	1	1
Nigeria	1	1	1
Egypt	2	2	2
Morocco	2	2	2
Algeria	2	2	2
Ethiopia	1	1	1
India	3	3	3
Japan	4	4	5
South Korea	4	4	5
China	3	3	3
Thailand	2	3	2
Singapore	4	5	5
United Kingdom	4	5	5
Germany	5	5	5
France	4	4	4
Netherlands	5	5	5
Sweden	5	5	5
Italy	4	4	4
Spain	4	4	4
Poland	3	3	3
Mexico	2	3	3
Brazil	2	3	3
Argentina	2	3	3
Chile	2	3	3
Colombia	1	2	3
United States	5	5	5
Canada	5	5	5
Australia	4	4	4
New Zealand	3	3	3
Greece	3	3	3
Rwanda	1	1	1
Uganda	1	1	1
Serbia	2	3	3
Saudi Arabia	4	4	4
UAE	4	4	4
Syria	1	1	1
Indonesia	2	2	2
Vietnam	2	2	3
Philippines	2	2	3
Russia	4	4	4
Malaysia	3	2	3

International Cancer Patient Coalition

Kenya

Survival Rates, Early Detection and Palliative Care



Strengths

- Increased use of PSA testing in private clinics has enabled earlier diagnoses in urban populations.
- Civil society and community health workers provide palliative support in high-burden counties.

Weakness

- Most men present at late or metastatic stages, drastically reducing survival.
- Weak referral systems and long waiting times delay initiation of treatment.

S W O T

Opportunity

- Train more community health volunteers in male cancer signs and early referral.
- Integrate palliative care training into nursing and clinical officer curricula.

Threats

- Stigma and low male health-seeking behavior prevent early consultation.
- Palliative care availability remains heavily urban-biased and donor-dependent.

5. High survival rates, strong early detection programs, and well-established palliative care services. Patients have access to timely diagnosis, advanced treatments, and comprehensive end-of-life care.

4. Good survival rates, effective early detection efforts, and accessible but regionally limited palliative care. Some disparities may exist in rural areas or for specific cancer types.

3. Moderate survival rates, early detection available but not widespread, and palliative care services mainly in urban centers. Some patients experience delays in diagnosis or limited end-of-life care.

2. Low survival rates, early detection efforts are inconsistent or underfunded, and palliative care is minimal or only available in select hospitals. Cancer patients face significant access barriers.

1. Very low survival rates, poor early detection infrastructure, and almost no palliative care services. Many patients are diagnosed late and lack proper support for pain management and end-of-life care.

Country	Survival Rates	Early Detection	Palliative Care
South Africa	2	3	2
Kenya	1	1	1
Nigeria	1	1	1
Egypt	2	2	2
Morocco	2	2	2
Algeria	2	2	2
Ethiopia	1	1	1
India	3	3	3
Japan	5	4	5
South Korea	5	4	4
China	3	3	4
Thailand	2	2	2
Singapore	5	5	5
United Kingdom	5	5	5
Germany	5	5	5
France	5	4	4
Netherlands	5	5	5
Sweden	5	5	5
Italy	5	4	5
Spain	5	4	5
Poland	3	3	3
Mexico	2	2	2
Brazil	3	3	3
Argentina	3	3	3
Chile	3	3	3
Colombia	2	2	2
United States	5	5	5
Canada	5	5	5
Australia	5	4	4
New Zealand	4	4	3
Greece	3	3	3
Rwanda	1	1	1
Uganda	1	1	1
Serbia	2	3	2
Saudi Arabia	4	4	4
UAE	4	4	4
Syria	1	1	1
Indonesia	2	2	2
Vietnam	2	2	2
Philippines	2	2	2
Russia	4	4	3
Malaysia	3	2	3

International Cancer Patient Coalition

Kenya

Utilization of Biomarkers



Strengths

- PSA testing is the main biomarker used and available in many private and some public facilities.
- Some regional cancer centers are beginning to discuss molecular testing through pilot studies.

Weakness

- No routine access to BRCA1/2, PTEN, or TMPRSS2-ERG testing in prostate cancer care.
- Even PSA is underused in rural health settings due to cost or provider training gaps.

S W O T

Opportunity

- Introduce risk-based screening and targeted biomarker use for high-risk patients (e.g., strong family history, younger onset).
- Develop regional biobanking and genomic testing labs through partnerships with African cancer genomics initiatives.
- `

Threats

- Cost and lack of lab infrastructure hinder national adoption of molecular biomarkers.
- Lack of awareness among clinicians regarding the use of PTEN or TMPRSS2-ERG in guiding treatment

Moderate utilization, often restricted to major hospitals or private healthcare settings. Some patients may not receive biomarker testing due to cost or limited availability in public healthcare systems.

Biomarker testing is available but underutilized, with significant barriers such as high costs, lack of awareness, or limited infrastructure. Many patients may not receive recommended biomarker assessments.

Biomarker testing is rarely performed, often due to lack of infrastructure, awareness, or financial barriers. Patients typically do not receive targeted therapies based on biomarker status.



International Cancer Patient Coalition

Kenya

Clinical Guidelines



Strengths

- Kenya's Ministry of Health has included prostate cancer in the National Cancer Control Strategy.
- Some county-level hospitals follow simplified treatment protocols developed by MOH or regional teaching hospitals.

Weakness

- No standardized, widely disseminated clinical guidelines specifically for prostate cancer screening and management.
- Guidelines (where present) may not include biomarker-based decision-making or reflect latest global evidence.

S W O T

Opportunity

- Formulate national prostate cancer-specific clinical guidelines, incorporating genetic markers and low-resource adaptations.
- Link training on these guidelines with CME credits to incentivize uptake.

Threats

- Discrepancies in practice between urban private centers and under-resourced public clinics.
- Updates to international guidelines may not be adopted quickly due to regulatory lags.

	Very High	High	Medium	Low	Very Low
Clinical Guideline Implementation	✖	✖	✖	O	✖
Feasibility of Integration	✖	✖	✖	O	✖
Adoption of International Guidelines	✖	✖	✖	O	✖
Engagement with Updates	✖	✖	✖	✖	O
ESMO Guidelines Implementation	✖	✖	✖	✖	O

International Cancer Patient Coalition

Kenya

Reimbursement

Strengths

- NHIF (National Hospital Insurance Fund) covers part of the cost for PSA tests, diagnostics, and limited treatment in public hospitals.
- NHIF reforms are gradually expanding cancer benefits, especially for in-patient services.

Weakness

- Many out-of-pocket costs remain for surgery, imaging, hormone therapy, and advanced drugs.
- BRCA1/2 and genetic test reimbursement is nonexistent for prostate cancer.

S W O T

Opportunity

- Expand NHIF coverage to include biomarker testing and outpatient prostate cancer care.
- Create subsidies or voucher programs for rural low-income men needing diagnosis or treatment.

Threats

- Rising cost of cancer care may strain NHIF's sustainability without reforms.
- Poor understanding of insurance benefits leads to underutilization, even when eligible.

● A structured reimbursement system exists, ensuring biomarker testing is covered through national healthcare systems, insurance, or public-private partnerships. Patients face no direct financial burden.

● A reimbursement framework is in place, but patients may still have out-of-pocket expenses such as co-pays, limited coverage, or financial caps on testing.

● No formal reimbursement system exists, meaning patients must fully cover the cost of biomarker testing out-of-pocket.

Country	Reimbursement Framework	No-cost Access
United States	●	○
United Kingdom	●	●
Canada	●	●
Australia	●	●
Germany	●	●
France	●	●
Netherlands	●	●
Sweden	●	●
Italy	●	●
Spain	●	●
Poland	●	●
Japan	●	●
South Korea	●	●
China	●	●
India	○	○
Singapore	●	●
Thailand	●	●
South Africa	○	○
Kenya	○	○
Nigeria	○	○
Egypt	○	○
Morocco	○	○
Algeria	●	●
Ethiopia	○	○
Mexico	●	●
Brazil	●	●
Argentina	●	●
Chile	●	●
Colombia	●	●
New Zealand	●	●
Greece	●	●
Rwanda	○	○
Uganda	○	○
Serbia	●	●
Saudi Arabia	●	●
UAE	●	●
Syria	○	○
Indonesia	●	○
Vietnam	●	○
Philippines	○	○
Russia	●	●
Malaysia	●	●

International Cancer Patient Coalition

Kenya

Prostate Cancer Screening

Strengths

- PSA testing available in major diagnostic labs; some county health departments conduct free screening camps.
- Increasing inclusion of prostate awareness in Men's Health Month activities.

Weakness

- No national prostate cancer screening program or protocol based on age or risk factors.
- Screening camps are episodic and not part of a follow-up continuum of care.



Opportunity

- Launch age-targeted national screening guidelines for men above 50, especially those with family history.
- Train primary health workers and clinical officers in PSA interpretation and follow-up pathways.

Threats

- Overdiagnosis and lack of treatment options may discourage policy-level support for national screening.
- Unequal access could widen urban-rural disparities if implemented without equity planning.

Country	Prostate Cancer Screening
United States	Annual LDCT (50-80 years, high-risk smokers)
United Kingdom	LDCT for high-risk individuals (55-74 years)
Canada	LDCT for high-risk individuals (55-74 years)
Australia	No national program, high-risk groups advised LDCT
Germany	No national program, under evaluation
France	No national LDCT screening
Netherlands	Participating in European screening studies
Sweden	No national LDCT screening
Italy	Regional pilot LDCT screening
Spain	No national LDCT program
Poland	No national program
Japan	No national LDCT program
South Korea	LDCT for high-risk individuals (50-74 years)
China	No national LDCT program
India	No national LDCT program
Singapore	No national LDCT program
Saudi Arabia	No national LDCT program; some hospital-based opportunistic screening
UAE	No national LDCT program; early-stage pilot studies ongoing in select hospitals
Syria	No national LDCT program; screening not prioritized due to conflict
Malaysia	No program; high-risk CT pilots

Country	Prostate Cancer Screening
Thailand	No national LDCT program
South Africa	No national LDCT program
Kenya	No national LDCT program
Nigeria	No national LDCT program
Egypt	No national LDCT program
Morocco	No national LDCT program
Algeria	No national LDCT program
Ethiopia	No national LDCT program
Mexico	No national LDCT program
Brazil	No national LDCT program
Argentina	No national LDCT program
Chile	No national LDCT program
Colombia	No national LDCT program
New Zealand	No national LDCT program
Greece	No national LDCT program
Rwanda	No national LDCT program
Uganda	No national LDCT program
Serbia	No national LDCT program
Indonesia	No national LDCT program; opportunistic screening in private sector
Vietnam	No national LDCT program; early pilot screening studies in Hanoi and Ho Chi Minh
Philippines	No national LDCT program; feasibility and awareness programs under discussion
Russia	No formal national LDCT program; regional pilot screening programs in large cities